Loading…
Lobbying Spend
—
Filings
13
Firms Hired
2
Active Period
2015–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 34, the 21st Century Cures Act Policy issues relation to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals
Client expense: — · Firm income: $50,000
Matched citations: H.R. 34
H.R. 6, the 21st Century Cures Act Policy issues relation to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals
Client expense: — · Firm income: $50,000
Matched citations: H.R. 6
H.R. 6, the "21st Century Cures Act." Policy issues relating Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
H.R. 6, the 21st Century Cures Act Policy issues relation to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals
Client expense: — · Firm income: $20,000
Matched citations: H.R. 6
H.R. 6, the "21st Century Cures Act." Policy issues relating Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
H.R. 6, the "21st Century Cures Act." Policy issues relating Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
H.R. 6, the "21st Century Cures Act." Policy issues relating to FDA's "Breakthrough Therapy" designation for pharmaceuticals.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Source: Senate LDA